1. Home
  2. SGA vs SER Comparison

SGA vs SER Comparison

Compare SGA & SER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Saga Communications Inc. (FL)

SGA

Saga Communications Inc. (FL)

N/A

Current Price

$8.35

Market Cap

56.6M

ML Signal

N/A

Logo Serina Therapeutics Inc.

SER

Serina Therapeutics Inc.

N/A

Current Price

$2.00

Market Cap

56.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SGA
SER
Founded
1986
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Broadcasting
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
56.6M
56.4M
IPO Year
1994
2024

Fundamental Metrics

Financial Performance
Metric
SGA
SER
Price
$8.35
$2.00
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
★ $9.50
AVG Volume (30 Days)
7.9K
★ 33.3K
Earning Date
11-05-2026
11-12-2026
Dividend Yield
★ 11.90%
N/A
EPS Growth
N/A
★ N/A
EPS
★ N/A
N/A
Revenue
★ $124,829,000.00
$130,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$0.99
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
5.65
★ 132.14
52 Week Low
$8.08
$1.22
52 Week High
$12.99
$5.31

Technical Indicators

Market Signals
Indicator
SGA
SER
Relative Strength Index (RSI) 41.64 39.25
Support Level $8.20 $1.93
Resistance Level $9.41 $2.01
Average True Range (ATR) 0.20 0.13
MACD -0.01 -0.00
Stochastic Oscillator 21.50 10.43

Price Performance

Historical Comparison
SGA
SER

About SGA Saga Communications Inc. (FL)

Saga Communications Inc is a broadcast company engaged in acquiring, developing, and operating broadcast properties. The company's objective is to operate top billing radio stations in mid-sized markets. It derives a majority of its revenue from the sale of advertising for broadcast on its stations.

About SER Serina Therapeutics Inc.

Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The company has one reportable segment relating to the research and development of its POZ platform. The segment derives its revenues from Grant revenue. Its main product candidate, SER-252 for advanced Parkinson's disease, is anticipated to enter clinical trials.

Share on Social Networks: